In reporting an 8% first-quarter earnings decline to shareholders, Novartis acknowledged the company's inability to meet GMPs at a variety of plants played a big role in that dip.
With the completion of inspections Jan. 20, Novartis Consumer Health ($NVS) set about reviewing the 483 FDA observations of its idled plant in Lincoln, NE. The plant was voluntarily closed Dec. 19 to...
The Novartis ($NVS) Nebraska plant closed in December because a host of over-the-counter products contained stray pieces from other drugs is expected to reopen this summer. Twice in recent days...